Benzinga | Mar 1, 2021 11:52AM EST

Oppenheimer Maintains Outperform on Mirati Therapeutics, Lowers Price Target to $255

Oppenheimer analyst Jay Olson maintains Mirati Therapeutics (NASDAQ:MRTX) with a Outperform and lowers the price target from $260 to $255.